Andes-1537(Andes-1537) - _专利_临床

概要

基本信息

药物类型

ASO

别名

Mulnitorsen、ANDES 1537、ASO-1537S

靶点-

作用方式

刺激剂

作用机制

细胞凋亡刺激剂、RNAi(RNA干扰)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症-

非在研适应症

晚期恶性实体瘤胆囊癌结肠转移性腺癌+ [4]

原研机构

Andes Biotechnologies SA

在研机构-

非在研机构

Andes Biotechnologies SA

权益机构-

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

使用我们的RNA技术数据为新药研发加速。

登录

或

查看完整样例数据

Sequence Code 29706596

来源: *****

关联

2

项与 Andes-1537 相关的临床试验

NCT03985072

/ Completed临床1期

Phase 1 Open-label Two-stage Safety and Tolerability Study With Subcutaneous Administration of Andes-1537 for Injection in Patients With Specific Types of Advanced Solid Tumors That Are Refractory To or No Available Standard Therapy

The study is a Phase 1 Open-label Two-stage, Safety and Tolerability Study with Cancer Type-specific Cohorts, Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Solid Tumors that are Refractory to Standard Therapy or For Which No Standard Therapy Is Available. Patients with unresectable solid tumors that are refractory or have failed standard therapy and are deemed non-eligible or intolerant to further therapy or for which no standard therapy is available will be included in 5 cancer type-specific parallel cohorts. The following tumor types will be evaluated for potential inclusion in each cancer type-specific cohort: gallbladder & biliary tract carcinoma; cervical carcinoma; gastric carcinoma; pancreatic carcinoma, and colorectal carcinoma.

开始日期2019-04-26

申办/合作机构

Andes Biotechnologies SA

NCT02508441

/ Terminated临床1期

A Phase 1 Open-label First-in-human Dose-escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available

This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors that are refractory to standard therapy or for which no standard therapy is available.

开始日期2015-12-08

申办/合作机构

Andes Biotechnologies SA

100 项与 Andes-1537 相关的临床结果

登录后查看更多信息

100 项与 Andes-1537 相关的转化医学

登录后查看更多信息

100 项与 Andes-1537 相关的专利（医药）

登录后查看更多信息

100 项与 Andes-1537 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床1期	智利	Andes Biotechnologies SA	2019-04-26
胆囊癌	临床1期	智利	Andes Biotechnologies SA	2019-04-26
结肠转移性腺癌	临床1期	智利	Andes Biotechnologies SA	2019-04-26
胰腺腺癌	临床1期	智利	Andes Biotechnologies SA	2019-04-26
复发性胃癌	临床1期	智利	Andes Biotechnologies SA	2019-04-26
宫颈癌	临床1期	智利	Andes Biotechnologies SA	2019-04-26
实体瘤	临床1期	美国	Andes Biotechnologies SA	2015-12-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02508441 (ASCO2018)	临床1期	HR阳性/HER2低表达实体瘤	22	Andes-1537	廠餘壓糧衊製廠獵繭鹹(膚觸遞餘網餘鹽壓鑰齋) = Two dose-limiting toxicities occurred at the 800 mg dose level both of which were injection site reactions: one precluding full cycle 1 dose delivery, and one involving grade 3 skin necrosis due to vascular occlusion and inflammation. 艱鑰醖繭遞餘餘顧襯製 (繭糧獵築鑰鑰餘顧鹹糧 ) 更多	积极	2018-06-01